Table 1.
Protein | Score | Normal (N=13) | Hyperplasia (Low grade) (N=20) | Dysplasia (High Grade) (N=12) | Adenocarcinoma (N=27) |
---|---|---|---|---|---|
eIF4E | 0 | 13 (100%) | 6 (30%) | 4 (33.33%) | 3 (11.11%) |
1 | 0 (0%) | 10 (50%) | 0 (0%) | 6 (22.22%) | |
2 | 0 (0%) | 4 (20%) | 8 (66.67%) | 6 (22.22%) | |
3 | 0 (0%) | 0 (0%) | 0 (0%) | 12 (44.45%) | |
4E‐BP1 | 0 | 13 (100%) | 5 (25%) | 1 (8.33%) | 15 (55.56%) |
1 | 0 (0%) | 8 (40%) | 2 (16.67%) | 8 (29.63%) | |
2 | 0 (0%) | 6 (30%) | 6 (50%) | 4 (14.81%) | |
3 | 0 (0%) | 1 (5%) | 3 (25%) | 0 (0%) | |
p‐eIF4E | 0 | 13 (100%) | 20 (100%) | 12 (100%) | 27 (100%) |
1 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
2 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
3 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
p‐4E‐BP1 | 0 | 13 (100%) | 6 (30%) | 3 (25%) | 15 (55.56%) |
1 | 0 (0%) | 8 (40%) | 1 (8.33%) | 2 (7.41%) | |
2 | 0 (0%) | 6 (30%) | 5 (41.67%) | 4 (14.81%) | |
3 | 0 (0%) | 0 (0%) | 3 (25%) | 6 (22.22%) |